Neville Rodie & Shaw Inc. Has $20.66 Million Stock Holdings in Eli Lilly and Company $LLY

Neville Rodie & Shaw Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 17.1% in the second quarter, Holdings Channel.com reports. The fund owned 17,226 shares of the company’s stock after selling 3,564 shares during the quarter. Eli Lilly and Company accounts for approximately 1.3% of Neville Rodie & Shaw Inc.’s portfolio, making the stock its 19th largest position. Neville Rodie & Shaw Inc.’s holdings in Eli Lilly and Company were worth $20,662,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in LLY. jvl associates llc increased its stake in Eli Lilly and Company by 15.1% in the second quarter. jvl associates llc now owns 655 shares of the company’s stock valued at $786,000 after acquiring an additional 86 shares during the period. Hobart Private Capital LLC lifted its stake in Eli Lilly and Company by 4.3% during the second quarter. Hobart Private Capital LLC now owns 2,719 shares of the company’s stock worth $3,261,000 after purchasing an additional 111 shares during the period. Vigilare Wealth Management lifted its stake in Eli Lilly and Company by 1.6% during the second quarter. Vigilare Wealth Management now owns 1,369 shares of the company’s stock worth $1,642,000 after purchasing an additional 21 shares during the period. Private Client Services LLC boosted its holdings in Eli Lilly and Company by 6.0% during the second quarter. Private Client Services LLC now owns 881 shares of the company’s stock valued at $1,057,000 after purchasing an additional 50 shares in the last quarter. Finally, Meadowbrook Wealth Management LLC boosted its holdings in Eli Lilly and Company by 110.8% during the second quarter. Meadowbrook Wealth Management LLC now owns 3,268 shares of the company’s stock valued at $3,920,000 after purchasing an additional 1,718 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 2.3%

NYSE:LLY opened at $1,122.32 on Tuesday. The stock’s fifty day moving average price is $1,153.77 and its two-hundred day moving average price is $1,044.22. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,249.45. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The company has a market cap of $1.06 trillion, a price-to-earnings ratio of 39.87, a P/E/G ratio of 1.43 and a beta of 0.51.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Wall Street Analysts Forecast Growth

LLY has been the subject of several analyst reports. Wolfe Research restated an “outperform” rating and set a $1,350.00 target price on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Berenberg Bank upped their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research report on Monday, June 22nd. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Royal Bank Of Canada lifted their price objective on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a report on Wednesday, July 8th. Finally, Leerink Partners boosted their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,283.64.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly plans to provide limited early access to experimental obesity drug retatrutide before potential U.S. FDA approval. The next-generation therapy could strengthen Lilly’s leadership in the rapidly expanding obesity market, although early access does not guarantee regulatory approval. Eli Lilly to offer early access to next-gen obesity drug to some patients
• Positive Sentiment: The FDA granted Breakthrough Therapy designation to olomorasib for previously treated patients with advanced pancreatic cancer carrying KRAS G12C mutations. The designation may accelerate development and regulatory review of Lilly’s investigational cancer treatment, expanding its pipeline beyond diabetes and obesity. Lilly’s olomorasib receives FDA Breakthrough Therapy designation
• Positive Sentiment: Investor attention remains focused on strong demand for Mounjaro and Zepbound, which are expected to drive second-quarter revenue and earnings growth. Lilly’s recent results showed rapid year-over-year expansion, while several analysts maintain price targets above current trading levels. Will Mounjaro and Zepbound Drive Lilly’s Q2 Results
• Neutral Sentiment: LLY is approaching a major earnings catalyst. Market commentary points to potential upside if sales exceed expectations but also warns that the stock could experience a large move in either direction because strong growth expectations are already embedded in its valuation. Eli Lilly Could Swing Over $76 Billion in Value After Earnings
• Negative Sentiment: Valuation analyses suggest the stock may be priced above estimates of its cash-flow-based intrinsic value after rising more than 300% over five years. This raises the bar for earnings, guidance and future obesity-drug growth. Eli Lilly Stock Looks Below Fair Value on Cash Flow
• Negative Sentiment: Novo Nordisk is attempting to regain momentum in the obesity-drug race, potentially increasing pricing and market-share pressure on Lilly. Separately, an executive’s recent open-market sale provides a modest negative sentiment signal, though it does not establish a change in company fundamentals. Obesity battle heats up as Novo competes with Lilly

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.